RE: Affyxell / Apicell13 Feb 2022 11:07
Therapeutics ?Apicell Therapeutics is a next-generation cell gene therapy development company. Based on Daewoong Pharmaceutical's mesenchymal stem cell platform 'DW-MSC' technology, 'Affimer' is a fusion of Avacta's Affimer platform technology, a type of non-immunoglobulin scaffold protein, to strengthen immune regulation function. Cell (AffyXell) is developed.
Both companies' technologies have overcome existing limitations. 'DW-MSC' overcomes the short lifespan and productivity limitations of existing adult tissue-derived mesenchymal stem cells, and 'Apimer' plays the same role as an antibody, but has advantages in tissue storage due to its low price and small size. The goal is to develop a therapeutic agent for diseases related to immunity and inflammation with a clear mechanism of action by synergizing the immunomodulatory function of DW-MSC and the target activation control function of Apimer.
-The meaning (background) of the company name is
?AffyXell is the name of the company as well as the name of the treatment platform to be developed. The word Affy means 'trust, betrothed' and broadly means fusion. X represents the chromosomes in our body and means the development of new cells through genetic modification. By using X instead of C in Cell, it contains the will to create a new cell therapy product that has never been before by introducing a gene with a specific function.
-If there is a company with the closest business model.
? Stem cells are developing mesenchymal stem cells, which have excellent immunomodulatory functions, as therapeutic agents that mainly target immune diseases. Domestic related companies include Daewoong Pharmaceutical, Medipost, Green Cross Lab Cell, Kang Stem Biotech, SCM Life Sciences, and CHA Biotech. Recently, in the field of immune diseases, the development of therapeutics using 'CAR-Treg', which introduces a CAR gene into regulatory T cells, is also in progress.
- Please explain the current status of pipeline development.
?The first pipeline (AFX001) is developing a treatment for organ transplant rejection and graft-versus-host disease. We confirmed the final excellent drug apimer capable of exhibiting antagonistic action against mouse and human target proteins, and introduced it into DW-MSC to construct the apicell cell line. We are accelerating the production of samples and related R&D in order to start the evaluation of efficacy in in vivo experiments on the established cell lines within this year. It plans to complete preclinical trials in 2023 and apply for IND for phase 1 clinical trials in the second half of that year. It is also aiming to conclude a license out contract before the phase 1 clinical trial of AFX001 is completed.
-You completed Series A funding in February of this year. The additional funding plan is
?First of all, attracting 8 billion won in Series A investment is the biggest achievement this year. It laid a solid foundation for technology development, a
Sign In
Follow the stocks
